Company Overview and News

 
Eneabba Gas moves to boost funds before end of quarter

2017-09-25 proactiveinvestors.com.au
Eneabba Gas Ltd (ASX:ENB) has had a quiet September quarter, with the company now looking to boost its cash balance in the last remaining days.
Upvote Downvote

 
UIL Completes Transaction to Acquire Eneabba's Perth Basin Permit Interests

2016-09-09 rigzone
UIL Energy Ltd. reported Thursday that the company has completed the sale of shares agreement to acquire Eneabba Gas’ Perth Basin permit interests in Western Australia.
Upvote Downvote

 
Black Rock Mining Ltd now holds substantial stake in Eneabba Gas

2016-09-05 proactiveinvestors.com.au
Black Rock Mining Ltd (ASX:BKT) is focused on exploring and developing its Mahenge graphite project in Tanzania.
Upvote Downvote

 
Black Rock Mining Ltd completes divestment of Ocean Hill Permit

2016-08-28 proactiveinvestors.com.au
Black Rock Mining Ltd (ASX:BKT) is focused on exploring and developing its Mahenge graphite project in Tanzania.
Upvote Downvote

 
UIL to Complete Acquisition of Eneabba's Perth Basin Permit Interests Soon

2016-08-05 rigzone
UIL Energy Ltd., a junior exploration company, revealed Friday that the company indicated that the completion of the acquisition of Eneabba Gas Ltd.'s Perth Basin permit interests in Western Australia will be completed shortly.
Upvote Downvote

 
UIL, Eneabba Extend Deadline to Complete Acquisition of Perth Basin Permits

2016-07-26 rigzone
UIL Energy, a junior exploration company in Australia, announced Monday that the completion date for the Sale of Shares Agreement (SSA) with Eneabba Gas Ltd. to acquire the latter's permit interests in the Perth Basin, Western Australia has been extended to Aug. 31, 2016.
Upvote Downvote

 
Black Rock Mining Ltd divests non-core asset, gains cash and shares

2016-05-09 proactiveinvestors.com.au
Black Rock Mining Ltd (ASX:BKT) is focused on exploring and developing its Mahenge graphite project in Tanzania.
Upvote Downvote

 
Results of GM

2016-05-09 asx.com.au
Upvote Downvote

 
 
Prospectus

2016-04-07 asx.com.au
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...